Liquidia (NASDAQ:LQDA) Insider Sells $149,377.60 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 5,245 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $149,377.60. Following the sale, the insider directly owned 115,241 shares of the company’s stock, valued at $3,282,063.68. The trade was a 4.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Down 3.1%

Shares of NASDAQ:LQDA traded down $0.86 during midday trading on Tuesday, reaching $26.81. The company had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The stock’s fifty day moving average price is $63.40 and its 200-day moving average price is $61.76. The stock has a market capitalization of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61. Liquidia Corporation has a one year low of $21.94 and a one year high of $93.61.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company’s revenue was up 1842.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.49) earnings per share. Equities research analysts expect that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company raised its position in shares of Liquidia by 63.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after purchasing an additional 22,592 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $29,694,000. Seven Fleet Capital Management LP lifted its holdings in shares of Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after purchasing an additional 51,727 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Finally, Handelsbanken Fonder AB acquired a new position in Liquidia during the 2nd quarter valued at approximately $1,993,000. 64.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. HC Wainwright dropped their price target on Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, October 2nd. Bank of America lifted their price objective on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Royal Bank Of Canada set a $130.00 target price on shares of Liquidia in a research note on Friday, July 24th. Zacks Research lowered shares of Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $30.00 target price (down from $108.00) on shares of Liquidia in a report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $83.69.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).